Clinical Trials
438 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT03093909 2026-05-20
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05685602 2026-05-18
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06840886 2026-05-14
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
Phase 1 Recruiting
NCT03321643 2026-05-13
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03816358 2026-05-13
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03819465 2026-05-12
MAGELLAN
AstraZeneca
Phase 1 Active not recruiting
NCT04104672 2026-05-07
ARC-8
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT06624085 2026-05-04
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT07481383 2026-05-01
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Continuity Biosciences, LLC
Phase 1 Recruiting
NCT02495896 2026-04-29
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT07488884 2026-04-29
ResQ108B-PANC
ImmunityBio, Inc.
Phase 1 Not yet recruiting
NCT05867121 2026-04-27
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT00885066 2026-04-23
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
Centre Antoine Lacassagne
Phase 1 Completed
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05101551 2026-04-22
PARPAML
Stanford University
Phase 1 Recruiting
NCT07353294 2026-04-22
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1 Enrolling by invitation
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT06586515 2026-04-20
MOONRAY-01
Eli Lilly and Company
Phase 1 Recruiting
NCT04158635 2026-04-17
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT00479128 2026-04-16
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05497778 2026-04-16
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07532902 2026-04-16
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT01352962 2026-04-14
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT00878163 2026-04-13
GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01660971 2026-04-13
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02627443 2026-04-13
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03403049 2026-04-13
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Montefiore Medical Center
Phase 1 Completed
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06454383 2026-04-13
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT06639724 2026-04-07
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
University of California, San Diego
Phase 1 Recruiting
NCT02937272 2026-04-03
A Study of LY3200882 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04833582 2026-04-03
A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Completed
NCT07107750 2026-04-03
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT05839119 2026-04-02
TASUC-Neo
Brown University
Phase 1 Terminated
NCT06360354 2026-03-31
MTAPESTRY 103
Amgen
Phase 1 Recruiting
NCT05984602 2026-03-30
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NYU Langone Health
Phase 1 Active not recruiting
NCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT06917079 2026-03-23
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT05285358 2026-03-13
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
City of Hope Medical Center
Phase 1 Recruiting
NCT07024615 2026-03-13
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT01104350 2026-03-05
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT07144254 2026-03-02
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Emory University
Phase 1 Recruiting
NCT06308419 2026-02-25
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03233139 2026-02-12
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT02336087 2026-02-04
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Phase 1 Active not recruiting